Search Bar & Filters
Found 26 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
This trial investigates MZE829 capsules in adults with proteinuric chronic kidney disease who also carry the APOL1 high risk genotype, specifically G1G1, G2G2, or G1G2 variants. The study aims to evaluate the safety, tolerability, and impact on albuminuria, a marker of kidney damage, in this population. It is an open-label Phase 2 trial, meaning all participants receive the study drug and results will help determine its effects and safety profile. Participants receive MZE829 capsules orally in a single-group design. The study includes two cohorts one with chronic kidney disease alongside diabetes, and another with chronic kidney disease without diabetes. The treatment and monitoring occur over a 12-week period, during which the study team assesses drug safety and effects on albuminuria levels. During the trial, participants will be monitored for adverse events and tolerability from baseline through week 12. Researchers will also measure changes in urine albumin-to-creatinine ratio UACR to evaluate kidney function. Blood samples will be taken to assess plasma drug concentrations. The total participation time is approximately 12 weeks, focusing on safety and biological effects of MZE829.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.
Actively Recruiting
Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are evaluating the safety and long-term effectiveness of the VARIPULSE Catheter System in treating persistent atrial fibrillation PsAF, a heart rhythm disease. The study focuses on patients undergoing catheter ablation procedures involving pulmonary vein isolation PVI and superior vena cava isolation SVCI, with some also receiving posterior wall isolation PWI. Additionally, it assesses safety for those having a simultaneous left atrial appendage occlusion LAAO procedure to reduce stroke risk. Participants will receive catheter ablation treatment using the VARIPULSE Catheter System, which includes a bi-directional catheter and generator delivering pulsed field ablation. Two groups are studied one undergoing PVI and SVCI, and another receiving PVI, SVCI plus PWI. Some participants in both groups may also have a concurrent LAAO procedure using commercially available devices. Follow-up for all participants extends up to 36 months after the procedures. Throughout the study, participants will be monitored for early adverse events within about 7 days post-procedure and for occurrences of atrial tachyarrhythmia from 2 to 6 months after treatment. Quality of life changes will be evaluated at 12 months using a specific atrial fibrillation questionnaire. Researchers will also track safety and effectiveness over 3 years through regular assessments, which may include clinical visits, tests, and questionnaires to measure heart rhythm stability and stroke risk reduction.
Actively Recruiting
Researchers are evaluating BHV-8000 in adults aged 40 to 80 diagnosed with early Parkinsons disease. The study aims to determine if BHV-8000 is effective, safe, and tolerable as a treatment. This Phase 23 trial is led by Biohaven Therapeutics Ltd. and includes a double-blind phase followed by an open-label phase to assess the treatments impact over time. Participants will be randomly assigned to receive either BHV-8000 at doses of 10 mg or 20 mg taken orally, or a matching placebo during the 48-week double-blind phase. After this, all participants enter a 48-week open-label phase where they receive BHV-8000. This design allows comparison between the study drug and placebo, followed by extended access to the active treatment. During the study, participants will be regularly assessed for Parkinsons disease progression using the Movement Disorder Society-Unified Parkinsons Disease Rating Scale MDS-UPDRS and other clinical measures. Safety will be monitored through recording adverse events and laboratory tests up to 96 weeks. The primary outcome is the time to first worsening event on the MDS-UPDRS Part II within 48 weeks. Participants are expected to remain in the study for up to 96 weeks of observation and treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are studying the effects of prasinezumab, given as an intravenous infusion, in people aged 50 to 85 with early-stage Parkinsons disease who are already receiving stable levodopa treatment. The study aims to compare prasinezumab to a placebo to evaluate its safety, how the body processes the drug, and its impact on motor symptoms related to Parkinsons disease. Participants will be randomly assigned to receive either prasinezumab or a placebo through IV infusions during the double-blind treatment phase. After this phase, eligible participants can join an open-label extension where they receive prasinezumab. The study follows participants for at least 104 weeks, with infusions and assessments scheduled throughout this period. During the study, participants will have regular visits for motor function assessments using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and other measures. Researchers will monitor adverse events, infusion reactions, and the presence of antibodies against prasinezumab. Blood samples will be taken at multiple time points to measure drug levels and immune responses. The total study duration extends through 2031, including safety follow-up after the last dose.
1-10 of 26
1